Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...
Stockhead on MSN
Dr Boreham’s Crucible: 2025’s A-Z of biotechs
With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to 2025's highlights ...
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...
The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).
Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the ...
Hennion & Walsh CIO Kevin Mahn explains Morning Brief host Julie Hyman some of his investing outlooks for 2026, as he tries to "follow the money" on certain biotech and pharmaceutical trends. Also ...
In this week’s edition of InnovationRx, we look at a former Wall Street analyst’s $4 billion obesity drug company, the first ...
Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...
Allucent has strategically added executives to its C-suite and is deploying artificial intelligence tools to help small and ...
Most Americans likely will not benefit immediately from efforts to lower prescription prices. Administration officials expect ...
Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the ...
Veeva Systems (NYSE: VEEV) today announced that Novo Nordisk's International Operations business unit has committed to use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback